Effect of Δ 9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans

British Journal of Pharmacology

Volumn 156, Issue 1, 2009, Pages 153-162

  Beaumont, H ^b   Jensen, J ^c   Carlsson, A ^c   Ruth, M ^d   Lehmann, A ^c   Boeckxstaens, G E ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ASTRAZENECA R AND D   (Sweden)

^d Discovery Medicine   (Sweden)

Author keywords

9 tetrahydrocannabinol; Cannabinoid; Gastro oesophageal reflux disease; Transient lower oesophageal sphincter relaxation

Indexed keywords

11 HYDROXYTETRAHYDROCANNABINOL; 11 NOR 9 CARBOXYTETRAHYDROCANNABINOL; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR AGONIST; DRONABINOL; DRUG METABOLITE; PLACEBO; RIMONABANT; UNCLASSIFIED DRUG; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; ESOPHAGUS MANOMETRY; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; NAUSEA AND VOMITING; NONHUMAN; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE RELAXATION; SOMNOLENCE; STATISTICAL ANALYSIS; STOMACH DISTENSION; SWALLOWING; TACHYCARDIA; TANDEM MASS SPECTROMETRY; TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATION; VOLUNTEER; XEROSTOMIA; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; MUSCLE RELAXATION; PATHOPHYSIOLOGY; PH; PHYSIOLOGY; POSTPRANDIAL STATE; SPECIES DIFFERENCE;

ADULT; ANIMALS; DEGLUTITION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESOPHAGEAL SPHINCTER, LOWER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MUSCLE RELAXATION; PIPERIDINES; POSTPRANDIAL PERIOD; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; SPECIES SPECIFICITY; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 62249182719     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00010.x     Document Type: Article

References (32)

1. Abrahams TP, Partosoedarso ER, Hornby PJ (2002). Lower oesophageal sphincter relaxation evoked by stimulation of the dorsal motor nucleus of the vagus in ferrets. Neurogastroenterol Motil 14 : 295 304.
2. Blackshaw LA, Staunton E, Lehmann A, Dent J (1999). Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 277 : G867 G874.
3. Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Armdorfer RC et al. (1980). Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 65 : 256 267.
4. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK et al. (1982). Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 307 : 1547 1552.
5. Fan P (1995). Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73 : 907 910.
6. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77 : 299 318.
7. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42 : 327 360.
8. Heading RC (1999). Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl. 231 : 3 8.
9. Hirsch DP, Tytgat GN, Boeckxstaens GE (2002). Transient lower oesophageal sphincter relaxations - a pharmacological target for gastro-oesophageal reflux disease? Aliment Pharmacol Ther 16 : 17 26.
10. Holloway RH (2000). The anti-reflux barrier and mechanisms of gastro-oesophageal reflux. Baillieres Best. Pract Res Clin Gastroenterol 14 : 681 699.
11. Holloway RH (2001). Systemic pharmacomodulation of transient lower esophageal sphincter relaxations. Am J Med 111 (Suppl. 8A 178S 185S.
12. Holloway RH, Penagini R, Ireland AC (1995). Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 268 : G128 G133.
13. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J (2003). Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro- oesophageal reflux refractory to proton pump inhibitors. Gut 52 : 1397 1402.
14. Lehmann A, Antonsson M, Bremner-Danielsen M, Flardh M, Hansson-Branden L, Karrberg L (1999). Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 117 : 1147 1154.
15. Lehmann A, Blackshaw LA, Branden L, Carlsson A, Jensen J, Nygren E et al. (2002). Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 123 : 1129 1134.
16. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH (2000). Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 118 : 7 13.
17. Martin CJ, Patrikios J, Dent J (1986). Abolition of gas reflux and transient lower esophageal sphincter relaxation by vagal blockade in the dog. Gastroenterology 91 : 890 896. (Pubitemid 16014595)
18. Massa F, Monory K (2006). Endocannabinoids and the gastrointestinal tract. J Endocrinol Invest 29 : 47 57.
19. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J (1995). Transient lower esophageal sphincter relaxation. Gastroenterology 109 : 601 610.
20. Partosoedarso ER, Young RL, Blackshaw LA (2001). GABA(B) receptors on vagal afferent pathways: peripheral and central inhibition. Am J Physiol Gastrointest Liver Physiol 280 : G658 G668.
21. Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ (2003). Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 550 : 149 158.
22. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74 : 129 180.
23. Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 : 635 664.
24. Pertwee RG (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152 : 984 986.
25. Porter AC, Felder CC (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90 : 45 60.
26. Ruth M, Hamelin B, Rohss K, Lundell L (1998). The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 12 : 35 40.
27. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 : 1092 1101.
28. Tortorice PV, O'Connell MB (1990). Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10 : 129 145.
29. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323 : 16 21.
30. Van Sickle MD, Oland LD, Ho W, Hillard LJ, MacKie K, Davison JS et al. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121 : 767 774.
31. Vela MF, Tutuian R, Katz PO, Castell DO (2003). Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 17 : 243 251.
32. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH (2002). Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 50 : 19 24.